Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elezanumab - AbbVie

Next Previous
Drug Profile

Elezanumab - AbbVie

Alternative Names: ABT-555

Latest Information Update: 24 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Monoclonal antibodies; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action RGMA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ischaemic stroke; Multiple sclerosis; Spinal cord injuries

Most Recent Events

  • 23 Dec 2024 AbbVie completes a phase II trial for Ischaemic strokein USA, Australia, Canada, Japan, South Korea, Spain (IV) (NCT04309474) (EudraCT2019-003753-29)
  • 26 Oct 2022 Pooled data from two phase II trials, RADIUS-R and RADIUS-P in Relapsing and Progressive forms of multiple sclerosis were presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2022)
  • 28 Sep 2022 Elezanumab is still in phase II trial for Spinal cord injuries in Australia, Canada, Israel, Japan, South Korea, Spain, USA (IV) (NCT04295538)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top